New book by Larry Connors Click here Improve your trading - See how
The company recently announced that it is providing direct-to-consumer predictive genetic products in the Russian Federation through its exclusive licensee CyGene Russia, LLC (www.cygenedirect.ru) and is expecting to expand its presence in Eastern Europe and Asia.
The new alcohol-dependence product analyzes variations in seven genes known to be associated with an increased risk for excessive alcohol consumption, substance abuse and some of the related complications with these behaviors. It is targeted geographically to the Eurasian market, because the genes chosen for the test panel relate to the ethnic composition of the region.
"This new product fits with CyGene's mission of providing genetic tests that are based on solid science, and that provide information that people can actually use to improve their lives," said Martin Munzer, CyGene's president and CEO.
"Scientific research is showing that genetics plays an important role in the progression and treatment of alcoholism. Variations in the tested genes have been associated with alcohol metabolism, detoxification, brain stimulating effects and the conferred increased risk for excessive substance and alcohol consumption, as well as increased risk for alcohol-related damage to the liver and pancreas," he continued.
CyGene currently markets a variety of DNA predictive genetic test panels that provide consumers with information on genetic predisposition to treatable conditions. CyGene is the only consumer genetic testing provider that guarantees anonymity to its customers, while providing access to the most updated science at the lowest possible price. The new Alcohol Dependence DNA Analysis is priced at $130 retail. Distributors are being recruited throughout the region and are invited to contact CyGene for information on how they can participate in the sale of CyGene's products.
About CyGene Laboratories Inc.
CyGene Laboratories Inc., based in Coral Springs, Fla., is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. With five patents issued, CyGene's scientific expertise is in DNA analysis and diagnostic technologies. Incorporated in 1995, CyGene has been developing technology and introducing products that address the growing demand for genetic knowledge implementation and utilization. CyGene currently markets eight DNA predictive genetic test panels in accordance with its patent pending business model, sold direct to consumers and through physicians and other healthcare practitioners. CyGene's process offers customers access to the most updated science, guaranteeing their anonymity and keeping consumers on the cutting edge of genetic discoveries at the lowest possible price. The method allows customers who have purchased a previous genetic test panel a low cost upgrade to their genetic report as new genetic discoveries become available.
For more information about CyGene Laboratories and its products, visit the Company's Web site at www.CyGeneDirect.com.
The CyGene Laboratories Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6480
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: CyGene Laboratories, Inc.
Thorp & Company Heidi Armstrong (305) 446-2700 harmstrong@thorpco.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
